Reading Time: 5 minutesEvery year, the team works hard to build on the previous year’s success. This year we are excited to include a series of three ALS-FTD joint sessions, in collaboration with the International Society for Frontotemporal Dementias, in the programme. To give you a teaser of what is to come, we are taking a closer look at the plenary speakers in the ALS-FTD sessions at the Symposium. In this blog, we explore the topics they will be presenting and find out a little more about the speakers.
Category: Clinical Trials

Symposium Preview: Meet the Symposium Communications Ambassadors
Reading Time: 7 minutesEach year at the Symposium, there is a huge amount of research presented on a range of topics from across the globe. With the Symposium returning to an in-person event this year, we are keen to increase the number of updates we share for those not able to attend, including people living with and affected by MND.
To help us do this, we have launched a new Symposium Communications Ambassador Programme so we can bring more of the research from the Symposium to non-scientific audiences. This programme was open for applications from early career researchers working in MND, who were interested in helping us shine a light on MND research happening across the world. This year we have 5 early career researchers taking part in the Programme, who will gain experience and new skills in communicating research to different audiences. Before, during and after the Symposium our Ambassador’s will be helping us to share the latest research with the MND community.

Symposium Preview: Meet the ALS/MND Plenary Speakers…Part 2
Reading Time: 7 minutesEach year we invite plenary speakers who are experts in their fields to provide an overview on topics across MND research and clinical practice. This year we have 14 plenary speakers talking about ALS/MND who will discuss a wide range of topics from genetics to tissue biomarkers to improving clinical practice. In this second blog we will be taking a closer look at some of our plenary speakers this year and sharing more about the topics they will be discussing.

Reading Time: 6 minutesOn the 8 September 2023, members of the Research Development team at the MND Association attended the 4th UCL Queen Square Motor Neuron Disease Centre

Reading Time: 6 minutesQurAlis, a biotechnology company focused on developing precision medicines for MND and other neurodegenerative diseases, has announced the opening of a clinical trial in the

Reading Time: 7 minutesClinical trials are vital in the hunt for effective treatments of motor neurone disease. They provide the evidence needed to determine whether a drug is

Highlights from MND EnCouRage UK 2023
Reading Time: 5 minutesHi everyone! My name’s Katie and I recently joined the Association as a Supporter Information Officer. My role offers me a unique perspective as I

Reading Time: 5 minutesThe MND clinical trial landscape has grown vastly over the last decade and this has led to increased opportunities for people with MND to take

Reading Time: 6 minutesMND is a very complex disease, and in the UK there is still only one approved treatment so the need for more effective treatments remains

Reading Time: 5 minutesThe current pace of clinical trials means that there are now more trials testing potential drugs for MND in the UK than ever before. One